Today's Paper Latest Coronavirus Elections Cooking 🔵 Covid Classroom Families Core values Story ideas iPad Weather Newsletters Obits Puzzles Archive
ADVERTISEMENT
story.lead_photo.caption Republican candidate for U.S. Senate Sen. David Perdue speaks during a campaign rally on Friday, Nov. 13, 2020, in Cumming, Ga. (AP Photo/Brynn Anderson)

WASHINGTON -- As the coronavirus forced millions of people out of work, shuttered businesses and shrank the value of retirement accounts, the Dow Jones Industrial Average plunged to a three-year low in March.

But for Sen. David Perdue, R-Ga., the crisis in March signaled something else: a stock-buying opportunity.

And for the second time in less than two months, Perdue's timing was impeccable. He avoided a sharp loss and reaped a large gain by selling and then buying the same stock: Cardlytics, an Atlanta financial technology company on whose board of directors he once served.

On Jan. 23, as word spread through Congress that the coronavirus posed a major economic and public health threat, Perdue sold off $1 million to $5 million in Cardlytics stock at $86 a share before it plunged, according to congressional disclosures.

[CORONAVIRUS: Click here for our complete coverage » arkansasonline.com/coronavirus]

Weeks later, in March, after the company's stock plunged further following an unexpected leadership shake-up and lower-than-forecast earnings, Perdue bought the stock back for $30 a share, investing between $200,000 and $500,000.

Those shares have now more than quadrupled in value, closing at $123 a share Wednesday.

The Cardlytics transactions were just a slice of a large number of investment decisions made in the early days of the pandemic by Perdue and other senators. They stirred public outrage after it became clear that some members of Congress had been briefed on the economic and health threat the virus posed. The transactions were mentioned in a story published by the Intercept in May.

Now that Perdue is locked in a pitched battle for reelection in a Jan. 5 runoff, his trades during a public health and economic crisis have become an issue in what already has become a negative, expensive campaign that will determine which party controls the Senate.

There is no evidence that Perdue, who is among the wealthier members of the Senate, acted on information gained as a member of Congress or through his long-standing relationship with company officials. It's illegal to use nonpublic information gained as a company insider or member of Congress to make investment decisions.

But legal experts say the timing of his sale, the fact that he quickly bought Cardlytics stock back when it had lost two-thirds of its market value and his close ties to company officials all warrant scrutiny.

"This does seem suspicious," said John Coffee Jr., a Columbia University law school professor who specializes in corporate and securities issues. But he added, "You need more than suspicions to convict."

The Perdue campaign declined a request for an interview with the senator. In a statement, Perdue spokesman John Burke said the senator had been cleared of wrongdoing but did not provide details.

"The bi-partisan Senate Ethics Committee, [Justice Department] and SEC all independently and swiftly cleared Senator Perdue months ago, which was reported on," Burke said.

Perdue's opponent, Democrat Jon Ossoff, has seized on his stock trading while trying to brand him as a "crook."

Perdue is not the only senator on the ballot in Georgia. Sen. Kelly Loeffler, also a Republican, is running against Democrat Raphael Warnock in a bid to complete the remainder of retired Sen. Johnny Isakson's term.

Pattern of moves

Perdue's Cardlytics transactions fit into a broader pattern of stock moves he made when the coronavirus first struck the U.S.

At the time, Perdue publicly maintained that the economy was strong and praised President Donald Trump during a Feb. 24 interview on Fox News Channel for "executing the greatest economic turnaround in U.S. history."

A series of swift transactions in his portfolio told a different story, however, showing the senator dumped some company stocks, while investing in others -- like protective equipment maker DuPont and pharmaceutical company Pfizer -- that were poised to do well during the pandemic.

Perdue has previously said that outside financial advisers make most of his trades.

But Donna Nagy, an Indiana University law professor, said that type of arrangement doesn't preclude Perdue from directing an adviser to make specific transactions.

She said one way for members of Congress to avoid questions about their financial holdings is to put them in a blind trust, which Perdue has not done.

"All of these questions about the motivations behind our members of Congress and their personal securities trading could be alleviated if Congress passed a law that limited investments," said Nagy, who specializes in securities law.

"Ordinary citizens should not have to question members of Congress about their investments."

The issue was enough of a liability that Perdue abruptly sold off between $3.2 million and $9.4 million of his stock portfolio over a four-day period in mid-April, according to an Associated Press review of mandatory financial disclosures he has submitted to the Senate. He did not sell his stock in Cardlytics.

Perdue acquired 75,000 shares in Cardlytics through stock options offered for his service on the company's board from 2010 to 2014, when he stepped down after winning his Senate seat, Securities and Exchange Commission filings show.

The company, which at the time had not yet gone public, also offered him options that would become available in October 2020 and January 2022.

Perdue's latest financial disclosures do not indicate whether he has exercised the options that became available in October.

While Perdue left the company's board, he has maintained ties to some of its executives, who have donated more than $30,000 to his political committees. Donations made to Perdue account for nearly 80% of all giving to federal candidates by Cardlytics employees over the past decade, records show.

Republican candidate for U.S. Senate Sen. David Perdue speaks during a campaign rally on Friday, Nov. 13, 2020, in Cumming, Ga. Perdue and Democratic candidate Jon Ossoff are in a runoff election for the Senate seat in Georgia. (AP Photo/Brynn Anderson)
Republican candidate for U.S. Senate Sen. David Perdue speaks during a campaign rally on Friday, Nov. 13, 2020, in Cumming, Ga. Perdue and Democratic candidate Jon Ossoff are in a runoff election for the Senate seat in Georgia. (AP Photo/Brynn Anderson)
Republican candidate for U.S. Senate Sen. David Perdue speaks during a campaign rally on Friday, Nov. 13, 2020, in Cumming, Ga. Perdue and Democratic candidate Jon Ossoff are in a runoff election for the Senate seat in Georgia. (AP Photo/Brynn Anderson)
Republican candidate for U.S. Senate Sen. David Perdue speaks during a campaign rally on Friday, Nov. 13, 2020, in Cumming, Ga. Perdue and Democratic candidate Jon Ossoff are in a runoff election for the Senate seat in Georgia. (AP Photo/Brynn Anderson)
ADVERTISEMENT

Sponsor Content

COMMENTS - It looks like you're using Internet Explorer, which isn't compatible with the Democrat-Gazette commenting system. You can join the discussion by using another browser, like Firefox or Google Chrome.
It looks like you're using Microsoft Edge. The Democrat-Gazette commenting system is more compatible with Firefox and Google Chrome.
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT